Business
BridgeBio presents detailed positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) at European Society of Cardiology Congress 2023
- The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value
About this update from Bridgebio Pharma, Inc.
[{"type":"text","content":"- The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p","length":162,"tagName":"div"}]